
  
    
      
        Introduction_NNP
        Advances_NNS in_IN transplant-based_JJ therapy_NN for_IN type_NN 1_CD diabetes_NN mellitus_JJ [_NN 1_CD ]_NN and_CC a_DT dearth_NN of_IN
        cadaveric_JJ pancreatic_JJ islets_NNS of_IN Langerhans_NNP have_VBP focused_VBN interest_NN on_IN developing_VBG renewable_JJ
        sources_NNS of_IN transplant-ready_JJ islet-replacement_JJ tissues_NNS ._. Pancreatic_NNP islets_NNS derive_VB from_IN
        embryonic_JJ endoderm_NN ,_, but_CC display_NN features_NNS of_IN neurons_NNS ,_, including_VBG a_DT shared_VBN set_NN of_IN
        cell-autonomous_JJ developmental_NN regulators_NNS [_NN 2_CD ]_NN ._. Islets_NNP are_VBP the_DT principal_JJ source_NN of_IN insulin_NN in_IN
        humans_NNS ,_, but_CC in_IN some_DT invertebrate_NN species_NNS ,_, such_JJ as_IN 
        Drosophila_NNP ,_, brain_NN neurons_NNS are_VBP the_DT main_JJ source_NN of_IN circulating_VBG insulin_NN
        [_NN 3_CD ,_, 4_CD ]_NN ._. The_DT similarities_NNS between_IN islet_NN cells_NNS and_CC neurons_NNS are_VBP further_RBR underscored_VBN by_IN the_DT
        demonstration_NN of_IN insulin_NN gene_NN transcription_NN in_IN the_DT vertebrate_NN brain_NN [_NN 5_CD ]_NN ,_, although_IN it_PRP
        remains_VBZ unclear_JJ whether_IN these_DT vertebrate_NN neurons_NNS produce_VBP or_CC secrete_NN insulin_NN protein_NN [_NN 6_CD ]_NN ._.
        Moreover_RB ,_, recent_JJ studies_NNS also_RB suggest_VBP that_IN in_IN some_DT settings_NNS ,_, mouse_NN pancreatic_JJ epithelial_NN
        cells_NNS can_MD engender_NN neuron-like_JJ cells_NNS [_NN 7_CD ,_, 8_CD ]_NN ._. These_DT and_CC other_JJ findings_NNS [_NN 2_CD ]_NN suggest_VBP that_IN
        common_JJ ,_, ancient_JJ developmental_NN programs_NNS may_MD govern_VB the_DT differentiation_NN of_IN islet_NN cells_NNS and_CC
        neurons_NNS ._. Methods_NNP promoting_VBG neural_NN differentiation_NN by_IN embryonic_JJ stem_NN (_( ES_NNP )_) cells_NNS have_VBP been_VBN
        adapted_VBN [_NN 9_CD ,_, 10_CD ,_, 11_CD ,_, 12_CD ,_, 13_CD ]_NN to_TO derive_VB insulin-producing_JJ cells_NNS (_( IPCs_NNP )_) ,_, but_CC it_PRP remains_VBZ unclear_JJ
        whether_IN such_JJ IPCs_NNP were_VBD derived_VBN from_IN neural_NN progenitors_NNS ,_, or_CC whether_IN a_DT neural-based_JJ strategy_NN
        can_MD generate_VB transplantable_JJ human_JJ IPCs_NNP ._.
        Neural_NNP cells_NNS derive_VB from_IN multipotent_NN progenitor_NN cells_NNS ,_, and_CC recently_RB ,_, clonal_NN human_JJ neural_NN
        progenitor_NN cells_NNS that_WDT remained_VBD multipotent_NN and_CC karyotypically_RB stable_JJ through_IN at_IN least_JJS 15_CD
        passages_NNS were_VBD purified_JJ by_IN flow-cytometry-based_JJ methods_NNS [_NN 14_CD ]_NN ._. The_DT availability_NN of_IN human_JJ
        neural_NN progenitor_NN cells_NNS allowed_VBD us_PRP to_TO investigate_VB whether_IN inductive_JJ signals_NNS involved_VBN in_IN
        normal_JJ pathways_NNS of_IN islet_NN development_NN could_MD direct_VB these_DT neural_NN progenitors_NNS to_TO develop_VB into_IN
        glucose-responsive_JJ IPCs_NNP ._. Here_RB we_PRP describe_VBP experimental_JJ strategies_NNS for_IN developing_VBG IPCs_NNP
        directly_RB from_IN human_JJ neural_NN stem_NN cells_NNS ._.
      
      
        Methods_NNP
        All_DT studies_NNS were_VBD performed_VBN in_IN accordance_NN with_IN appropriate_JJ human_JJ participants_NNS '_POS approval_NN
        according_VBG to_TO Stanford_NNP University_NNP Institutional_NNP Review_NNP Board_NNP guidelines_NNS ._.
        
          Cell_NNP Lines_NNPS and_CC Culture_NNP Conditions_NNP
          The_DT human_JJ neurosphere_NN (_( NS_NNP )_) cell_NN lines_NNS (_( line_NN numbers_NNS 1651_CD ,_, 1664_CD ,_, and_CC 1673_CD )_) were_VBD
          established_VBN following_VBG enrichment_NN for_IN AC_NNP 133_CD
          +_NN cells_NNS ,_, as_RB previously_RB described_VBD [_NN 14_CD ]_NN ,_, although_IN none_NN of_IN the_DT cell_NN lines_NNS
          was_VBD expanded_VBN from_IN a_DT single_JJ cell_NN ,_, and_CC they_PRP are_VBP therefore_RB not_RB clonal_NN ._. The_DT different_JJ cell_NN
          lines_NNS were_VBD from_IN distinct_JJ donors_NNS and_CC karyotypically_RB normal_JJ ._. They_PRP gave_VBD comparable_JJ results_NNS ,_,
          but_CC line_NN 1664_CD produced_VBN less_JJR insulin_NN by_IN stage_NN 4_CD in_IN our_PRP$ protocol_NN than_IN the_DT other_JJ cell_NN lines_NNS ._.
          Following_VBG cell_NN thaw_NN ,_, NSs_NNP were_VBD expanded_VBN in_IN suspension_NN culture_NN ,_, and_CC in_IN each_DT case_NN were_VBD used_VBN
          between_IN passages_NNS 5_CD and_CC 7_CD ._. Undifferentiated_NNP human_JJ NS_NNP cells_NNS (_( stage_NN 1_LS )_) were_VBD cultured_JJ and_CC
          expanded_VBN in_IN medium_NN containing_VBG X-VIVO_NNP 15_CD (_( Cambrex_NNP ,_, Walkersville_NNP ,_, Maryland_NNP ,_, United_NNP States_NNPS )_) ,_,
          N_NNP 2_CD supplement_NN (_( Invitrogen_NNP ,_, Carlsbad_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ,_, 2_CD μg_NN /_NN ml_NN heparin_NN ,_, 10_CD
          ng_NN /_NN ml_NN leukemia_NN inhibitory_NN factor_NN (_( Chemicon_NNP ,_, Temecula_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ,_, 20_CD
          ng_NN /_NN ml_NN epidermal_NN growth_NN factor_NN (_( R_NN &_CC D_NNP Systems_NNPS ,_, Minneapolis_NNP ,_, Minnesota_NNP ,_, United_NNP States_NNPS )_) ,_,
          and_CC 20_CD ng_NN /_NN ml_NN fibroblast_NN growth_NN factor-_NN 2_CD (_( R_NN &_CC D_NNP Systems_NNPS )_) ,_, and_CC they_PRP were_VBD frozen_VBN after_IN
          enzymatic_JJ dissociation_NN ._. At_IN stage_NN 2_CD ,_, we_PRP thawed_JJ and_CC cultured_JJ 10_CD
          7_CD cells_NNS in_IN medium_NN made_VBN from_IN a_DT 1_CD :_: 1_CD mixture_NN of_IN glucose-free_JJ DMEM_NNP
          (_( Invitrogen_NNP )_) and_CC F-_NNP 12_CD medium_NN (_( Invitrogen_NNP )_) containing_VBG 0_CD ._. 2_CD %_NN bovine_JJ serum_NN albumin_NN (_( Sigma_NNP ,_,
          St_NNP ._. Louis_NNP ,_, Missouri_NNP ,_, United_NNP States_NNPS )_) ,_, N_NNP 2_CD supplement_NN ,_, 2_CD μg_NN /_NN ml_NN heparin_NN ,_, 10_CD ng_NN /_NN ml_NN leukemia_NN
          inhibitory_NN factor_NN ,_, 20_CD ng_NN /_NN ml_NN epidermal_NN growth_NN factor_NN ,_, and_CC 20_CD ng_NN /_NN ml_NN fibroblast_NN growth_NN
          factor-_NN 2_CD ._. The_DT final_JJ concentration_NN of_IN glucose_NN in_IN stage_NN 2_CD was_VBD 5_CD mM_NN ._. Cultures_NNP were_VBD fed_VBN
          weekly_JJ for_IN up_IN to_TO 2_CD wk_NN ._. Cells_NNP formed_VBD NSs_NNP during_IN stages_NNS 1_CD and_CC 2_CD ._. After_IN 2_CD wk_NN ,_, we_PRP transferred_VBD
          40_CD –_NN 80_CD NSs_NNP containing_VBG a_DT total_NN of_IN approximately_RB 2_CD –_NN 4_CD ×_NN 10_CD
          5_CD cells_NNS to_TO single_JJ wells_NNS in_IN plates_NNS coated_VBN with_IN 0_CD ._. 005_CD %_NN poly-_NN L-_NNP ornithine_NN
          (_( Sigma_NNP )_) and_CC 3_CD μg_NN /_NN ml_NN fibronectin_NN (_( Invitrogen_NNP )_) ._. These_DT were_VBD cultured_JJ for_IN 2_CD wk_NN (_( stage_NN 3_LS )_) in_IN a_DT
          1_CD :_: 1_CD mixture_NN of_IN low-glucose_JJ DMEM_NNP and_CC F-_NNP 12_CD media_NNS containing_VBG 100_CD mg_NN /_NN l_NN apo-transferrin_JJ
          (_( Sigma_NNP )_) ,_, 288_CD mg_NN /_NN l_NN glucose_NN ,_, 73_CD mg_NN /_NN l_NN 
          L_NNP -_: glutamine_NN ,_, 1_CD ._. 69_CD g_SYM /_NN l_NN sodium_NN bicarbonate_NN ,_, 25_CD μg_NN /_NN ml_NN bovine_JJ insulin_NN
          (_( Sigma_NNP )_) ,_, 20_CD nM_NN progesterone_NN ,_, 100_CD μM_NN putrescine_NN ,_, 30_CD nM_NN sodium_NN selenite_NN ,_, and_CC
          penicillin_NN /_NN streptomycin_NN ._. Stage_NN 3_CD medium_NN was_VBD supplemented_JJ with_IN 2_CD μM_NN all-_NN
          trans_NNS retinoic_JJ acid_NN (_( RA_NNP )_) (_( Sigma_NNP )_) and_CC had_VBD a_DT final_JJ glucose_NN concentration_NN
          of_IN either_DT 5_CD or_CC 17_CD mM_NN ._. At_IN stage_NN 4_CD ,_, cells_NNS were_VBD cultured_JJ in_IN N_NNP 2_CD medium_NN [_NN 10_CD ]_NN supplemented_JJ with_IN
          10_CD mM_NN nicotinamide_NN (_( Sigma_NNP )_) and_CC 10_CD nM_NN insulin-like_JJ growth_NN factor-_NN 1_CD (_( R_NN &_CC D_NNP Systems_NNPS )_) for_IN
          up_IN to_TO 6_CD d_SYM ._. Stage_NN 4_CD medium_NN included_VBD 17_CD ._. 3_LS mM_NN glucose_NN ._. During_IN stage_NN 3_CD and_CC 4_CD ,_, medium_NN was_VBD
          changed_VBN every_DT other_JJ day_NN ._. To_TO examine_VB the_DT effect_NN of_IN Sonic_NNP hedgehog_NN (_( Shh_NNP )_) (_( R_NN &_CC D_NNP Systems_NNPS )_) ,_,
          we_PRP added_VBD 300_CD nM_NN mouse_NN Shh_NNP in_IN PBS_NNP every_DT other_JJ day_NN during_IN stage_NN 4_CD ._. To_TO quantify_VB neurite_NN
          outgrowths_NNS per_IN cluster_NN ,_, 20_CD Shh-treated_NNP or_CC control_NN stage_NN 4_CD IPC_NNP clusters_NNS were_VBD photographed_VBN
          under_IN light_JJ microscopy_NN ,_, and_CC digitized_JJ images_NNS were_VBD used_VBN to_TO score_NN neurites_NNS ._. Data_NNP are_VBP
          presented_VBN as_IN the_DT average_NN ±_NN the_DT standard_JJ error_NN of_IN the_DT mean_NN ._. Two-tailed_NNP 
          t_NN tests_NNS were_VBD conducted_VBN to_TO determine_VB statistical_JJ significance_NN ._.
        
        
          RT-PCR_NNP
          Total_NNP RNA_NNP was_VBD prepared_VBN by_IN using_VBG TRIZOL_NNP (_( Invitrogen_NNP )_) and_CC RQ_NNP 1_CD RNase-free_NNP DNase_NNP (_( Promega_NNP ,_,
          Madison_NNP ,_, Wisconsin_NNP ,_, United_NNP States_NNPS )_) ._. For_IN cDNA_NN synthesis_NN ,_, random_JJ sequence_NN primers_NNS were_VBD used_VBN
          to_TO prime_JJ reverse_NN transcription_NN reactions_NNS and_CC synthesis_NN was_VBD carried_VBN out_IN by_IN Thermoscript_NNP RT_NNP
          (_( Invitrogen_NNP )_) ._. A_DT total_NN of_IN 35_CD cycles_NNS of_IN PCR_NNP were_VBD performed_VBN using_VBG Platinum_NN 
          Taq_NNP High_NNP Fidelity_NNP DNA_NNP Polymerase_NNP (_( Invitrogen_NNP )_) ._. GAPDH_NNP expression_NN was_VBD
          used_VBN to_TO normalize_VB input_NN template_NN cDNA_NN to_TO analyze_VB relative_JJ gene_NN expression_NN ._. Primer_NNP
          sequences_NNS and_CC gene_NN accession_NN numbers_NNS are_VBP listed_VBN in_IN Table_NNP 1_CD ._. To_TO confirm_VB their_PRP$ identity_NN ,_,
          DNA_NNP products_NNS from_IN PCR_NNP reactions_NNS were_VBD excised_VBN ,_, cloned_VBN ,_, and_CC sequenced_JJ ._.
        
        
          Immunohistochemistry_NNP and_CC Morphometry_NNP
          Cell_NNP clusters_NNS were_VBD fixed_VBN in_IN 4_CD %_NN paraformaldehyde_NN ,_, embedded_VBN in_IN HistoGel_NNP (_( Richard-_NNP Allan_NNP
          Scientific_NNP ,_, Kalamazoo_NNP ,_, Michigan_NNP ,_, United_NNP States_NNPS )_) ,_, and_CC then_RB embedded_VBN in_IN paraffin_NN ._. We_PRP
          performed_VBD immunohistochemistry_NN on_IN 6_CD -_: μm_NN tissue_NN sections_NNS ._. We_PRP used_VBD primary_JJ antibodies_NNS at_IN the_DT
          following_JJ dilutions_NNS :_: guinea_NN pig_NN anti-insulin_JJ ,_, 1_CD :_: 200_CD (_( Linco_NNP Research_NNP ,_, St_NNP ._. Charles_NNP ,_,
          Missouri_NNP ,_, United_NNP States_NNPS )_) ,_, mouse_NN anti-β-tubulin_JJ III_NNP ,_, 1_CD :_: 500_CD (_( Sigma_NNP )_) ;_: rabbit_NN anti-_NN C-_NNP peptide_NN ,_,
          1_CD :_: 100_CD (_( Linco_NNP Research_NNP )_) ;_: mouse_NN anti-_NN Nestin_NNP ,_, 1_CD :_: 200_CD (_( Chemicon_NNP )_) ;_: mouse_NN anti-_NN Ki_NNP 67_CD ,_, 1_CD :_: 100_CD
          (_( Novocastra_NNP ,_, Newcastle_NNP ,_, United_NNP Kingdom_NNP )_) ;_: rabbit_NN anti–cleaved_JJ caspase-_NN 3_CD ,_, 1_CD :_: 200_CD (_( Cell_NNP
          Signaling_NNP ,_, Beverly_NNP ,_, Massachusetts_NNP ,_, United_NNP States_NNPS )_) ;_: rabbit_NN anti-glucagon_JJ ,_, 1_CD :_: 200_CD (_( Dako_NNP ,_,
          Carpinteria_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ;_: rabbit_NN anti-_NN Glut-_NNP 2_CD ,_, 1_CD :_: 200_CD (_( ADI_NNP ,_, San_NNP Antonio_NNP ,_,
          Texas_NNP ,_, United_NNP States_NNPS )_) ;_: mouse_NN anti-proinsulin_JJ ,_, 1_CD :_: 500_CD (_( O_NNP ._. Madsen_NNP ,_, Hagedorn_NNP ,_, Gentofte_NNP ,_,
          Denmark_NNP )_) ;_: mouse_NN anti-glucokinase_JJ ,_, 1_CD :_: 200_CD (_( C_NNP ._. Newgard_NNP ,_, Duke_NNP University_NNP ,_, Durham_NNP ,_, North_NNP
          Carolina_NNP ,_, United_NNP States_NNPS )_) ;_: mouse_NN anti-_NN GFAP_NNP ,_, 1_CD :_: 1_CD ,_, 000_CD (_( Dako_NNP )_) ;_: mouse_NN anti-_NN MAP_NNP 2_CD ,_, 1_CD :_: 500_CD
          (_( Sigma_NNP )_) ;_: and_CC rabbit_NN anti-_NN Olig_NNP 2_CD ,_, 1_CD :_: 1_CD ,_, 000_CD (_( H_NNP ._. Takebayashi_NNP ,_, National_NNP Institute_NNP for_IN
          Physiological_NNP Sciences_NNPS ,_, Okazaki_NNP ,_, Japan_NNP )_) ._. Confocal_NNP immunofluorescence_NN microscopy_NN with_IN an_DT
          optical_JJ slice_NN thickness_NN of_IN 0_CD ._. 6_CD μm_NN was_VBD performed_VBN on_IN a_DT Bio-_NNP Rad_NNP (_( Hercules_NNP ,_, California_NNP ,_,
          United_NNP States_NNPS )_) MRC_NNP 1000_CD ._.
          Cell_NNP counting_VBG and_CC point-counting_JJ morphometry_NN were_VBD performed_VBN using_VBG standard_JJ
          morphometric_JJ techniques_NNS [_NN 15_CD ]_NN ._. To_TO obtain_VB representative_NN results_NNS ,_, all_DT quantification_NN of_IN
          immunostaining_VBG was_VBD performed_VBN by_IN counting_VBG numbers_NNS of_IN positive-stained_JJ cells_NNS and_CC dividing_VBG
          by_IN the_DT area_NN of_IN total_JJ tissues_NNS using_VBG a_DT standard_JJ 10_CD ×_NN 10_CD microscope_NN grid_NN ._. For_IN quantification_NN
          of_IN cells_NNS expressing_VBG Nestin_NNP ,_, Ki_NNP 67_CD ,_, β-tubulin_JJ III_NNP ,_, activated_VBN caspase-_NN 3_CD ,_, insulin_NN ,_, or_CC
          C-_NNP peptide_NN ,_, NS-derived_NNP cell_NN clusters_NNS were_VBD fixed_VBN ,_, and_CC sectioned_JJ to_TO generate_VB 7_CD -_: μm-thick_JJ
          tissue_NN sections_NNS ._. Appropriately_NNP stained_JJ cells_NNS were_VBD counted_VBN in_IN a_DT minimum_NN of_IN ten_CD random_JJ
          microscopic_JJ fields_NNS obtained_VBN from_IN at_IN least_JJS ten_CD cell_NN clusters_NNS per_IN condition_NN ._.
        
        
          In_IN Situ_NNP Hybridization_NNP
          We_PRP used_VBD human_JJ insulin_NN cDNA_NN (_( 320_CD bp_NN )_) cloned_VBN in_IN plasmid_NN pCR_NN 4_CD -_: TOPO_NNP (_( Invitrogen_NNP )_) as_IN a_DT
          template_NN for_IN in_IN vitro_NN transcription_NN to_TO produce_VB riboprobes_NNS with_IN a_DT digoxigenin-_NN RNA_NNP labeling_VBG
          kit_NN (_( Ambion_NNP ,_, Austin_NNP ,_, Texas_NNP ,_, United_NNP States_NNPS )_) ,_, performed_VBN hybridization_NN with_IN IPC_NNP cluster_NN
          sections_NNS as_IN described_VBN [_NN 16_CD ]_NN ,_, and_CC used_VBD DIG_NNP Nucleic_NNP Acid_NNP Detection_NNP Kit_NNP (_( Roche_NNP ,_, Indianapolis_NNP ,_,
          Indiana_NNP ,_, United_NNP States_NNPS )_) for_IN development_NN according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._.
        
        
          Insulin_NNP C-P_NNP eptide_NN Quantification_NNP and_CC In_IN Vitro_NNP Insulin_NNP Secretion_NNP Assay_NNP
          At_IN each_DT stage_NN ,_, 300_CD NS_NNP or_CC IPC_NNP clusters_NNS were_VBD handpicked_VBN ,_, washed_VBN with_IN PBS_NNP ,_, and_CC
          homogenized_JJ ;_: then_RB intracellular_NN C-_NNP peptide_NN content_NN was_VBD measured_VBN with_IN a_DT C-_NNP peptide_NN ELISA_NNP kit_NN
          (_( American_NNP Laboratory_NNP Products_NNPS Company_NN ,_, Windham_NNP ,_, New_NNP Hampshire_NNP ,_, United_NNP States_NNPS )_) ._. Stage_NN 4_CD
          IPC_NNP clusters_NNS were_VBD cultured_JJ in_IN glucose-free_JJ RPMI_NNP (_( Invitrogen_NNP )_) supplemented_JJ with_IN 2_CD ._. 8_CD mM_NN
          glucose_NN ,_, 20_CD mM_NN HEPES_NNP ,_, and_CC 10_CD %_NN newborn_JJ calf_NN serum_NN (_( Invitrogen_NNP )_) for_IN at_IN least_JJS 2_CD –_NN 3_CD h_NN ._. At_IN the_DT
          end_NN of_IN these_DT washes_NNS ,_, no_DT insulin_NN was_VBD detectable_JJ in_IN the_DT wash_NN supernatant_NN using_VBG an_DT ELISA_NNP kit_NN
          (_( American_NNP Laboratory_NNP Products_NNPS Company_NN )_) ._. Fifty_NNP IPC_NNP clusters_NNS were_VBD handpicked_VBN ,_, transferred_VBN
          to_TO a_DT 24_CD -_: well_RB plate_NN ,_, and_CC incubated_JJ for_IN 2_CD h_NN at_IN 37_CD °_NN C_NNP in_IN the_DT presence_NN of_IN 2_CD ._. 8_CD mM_NN glucose_NN ,_, 25_CD
          mM_NN glucose_NN ,_, or_CC 25_CD mM_NN sucrose_NN ._. Supernatants_NNP were_VBD then_RB harvested_VBN for_IN enzyme-linked_JJ
          immunosorption_NN assay_NN (_( ELISA_NNP )_) –_NN based_VBD quantification_NN of_IN released_VBN insulin_NN ._.
        
        
          IPC_NNP Transplantation_NNP and_CC Physiologic_NNP Tests_NNP
          All_DT animal_NN studies_NNS were_VBD performed_VBN in_IN accordance_NN with_IN Stanford_NNP University_NNP Animal_NNP Care_NNP
          and_CC Use_NN Guidelines_NNS ._. Under_IN general_JJ anesthesia_NN ,_, 9_CD -_: to_TO 10_CD -_: wk-old_JJ male_JJ NOD_NNP 
          scid_NN mice_NNS (_( purchased_VBN from_IN Jackson_NNP Laboratories_NNPS ,_, Bar_NNP Harbor_NNP ,_, Maine_NNP ,_,
          United_NNP States_NNPS )_) were_VBD engrafted_JJ with_IN 1_CD ,_, 000_CD handpicked_VBN IPC_NNP clusters_NNS in_IN the_DT right_NN and_CC left_VBD
          subcapsular_NN renal_JJ space_NN (_( 500_CD IPC_NNP clusters_NNS each_DT )_) or_CC received_VBD a_DT sham_NN transplant_NN of_IN saline_NN
          solution_NN ._. Transplantation_NNP of_IN more_JJR IPC_NNP clusters_NNS in_IN a_DT renal_JJ graft_NN site_NN was_VBD not_RB feasible_JJ
          because_IN of_IN the_DT size_NN of_IN the_DT clusters_NNS ._. Two_CD weeks_NNS after_IN IPC_NNP cluster_NN transplantation_NN ,_, we_PRP
          subjected_VBN mice_NNS to_TO an_DT overnight_JJ fast_RB ._. Then_RB we_PRP measured_VBD serum_NN human_JJ C-_NNP peptide_NN before_IN and_CC 30_CD
          min_NN after_IN intraperitoneal_NN injection_NN with_IN 3_CD g_SYM of_IN glucose_NN per_IN kilogram_NN of_IN body_NN weight_NN using_VBG
          a_DT human_JJ C-_NNP peptide_NN ELISA_NNP kit_NN ._. When_WRB stage_NN 4_CD IPC_NNP clusters_NNS were_VBD transplanted_VBN ,_, tumors_NNS were_VBD not_RB
          observed_VBN 4_CD wk_NN after_IN engraftment_NN ,_, the_DT maximum_NN period_NN of_IN observation_NN (_(
          n_NN =_SYM 5_LS )_) ._. All_DT data_NNS represent_VBP the_DT average_JJ (_( from_IN the_DT indicated_VBN number_NN of_IN
          samples_NNS )_) ±_NN standard_JJ error_NN of_IN the_DT mean_NN ._. Two-tailed_NNP 
          t_NN tests_NNS were_VBD conducted_VBN to_TO determine_VB statistical_JJ significance_NN ._.
        
      
      
        Results_NNS
        
          Glucose_NNP Restriction_NNP Initiates_NNP IPC_NNP Development_NNP
          Culture_NNP media_NNS with_IN high_JJ glucose_NN concentrations_NNS have_VBP been_VBN useful_JJ for_IN isolating_VBG and_CC
          maintaining_VBG progenitor_NN cell_NN populations_NNS from_IN the_DT central_JJ and_CC peripheral_JJ nervous_JJ systems_NNS
          [_NN 14_CD ,_, 17_CD ]_NN and_CC for_IN permitting_VBG differentiation_NN by_IN neurogenic_JJ cells_NNS [_NN 18_CD ]_NN ._. We_PRP routinely_RB
          expanded_VBD NS_NNP cultures_NNS in_IN medium_NN containing_VBG 37_CD mM_NN glucose_NN ,_, a_DT level_NN 5_CD -_: to_TO 6_CD -_: fold_VB higher_JJR than_IN
          physiologic_JJ glucose_NN concentration_NN ._. Isolated_NNP human_JJ neural_NN progenitors_NNS spontaneously_RB
          aggregate_JJ in_IN these_DT conditions_NNS to_TO produce_VB a_DT cell_NN cluster_NN called_VBD a_DT NS_NNP ,_, and_CC 85_CD %_NN –_NN 90_CD %_NN of_IN NS_NNP
          cells_NNS produce_VBP the_DT intermediary_JJ filament_NN Nestin_NNP (_( Figures_NNS 1_CD and_CC 2_LS )_) ,_, a_DT putative_JJ marker_NN of_IN
          neural_NN stem_NN and_CC progenitor_NN cells_NNS [_NN 19_CD ]_NN ._. Prolonged_NNP exposure_NN to_TO high_JJ glucose_NN levels_NNS can_MD also_RB
          severely_RB reduce_VB insulin_NN expression_NN in_IN pancreatic_JJ β-cells_JJ [_NN 20_CD ]_NN ._. Thus_RB ,_, we_PRP postulated_JJ that_DT
          glucose_NN reduction_NN might_MD blunt_VB neurogenic_JJ programs_NNS by_IN NSs_NNP and_CC promote_VB alternate_JJ fates_NNS ,_,
          including_VBG development_NN of_IN IPCs_NNP ._. Therefore_RB ,_, we_PRP switched_VBD NS_NNP culture_NN conditions_NNS from_IN high_JJ
          glucose_NN (_( 37_CD mM_NN ,_, “ stage_NN 1_LS” )_) to_TO low_JJ glucose_NN (_( 5_CD mM_NN ,_, “ stage_NN 2_CD” ;_: see_VB Figure_NN 1_CD A_DT )_) to_TO initiate_VB
          development_NN ._.
          To_TO assess_VB developmental_NN changes_NNS resulting_VBG from_IN glucose_NN reduction_NN and_CC later_RB culture_NN
          modifications_NNS ,_, we_PRP examined_VBD NS_NNP cell_NN composition_NN ,_, and_CC expression_NN of_IN gene_NN products_NNS known_VBN to_TO
          regulate_VB or_CC define_VB in_IN vivo_NN fates_NNS of_IN embryonic_JJ neural_NN or_CC islet_NN cells_NNS ._. A_DT β-tubulin_JJ III_NNP
          isoform_NN produced_VBN in_IN differentiating_VBG neurons_NNS was_VBD not_RB detected_VBN in_IN stage_NN 1_CD cells_NNS ,_, whereas_IN
          expression_NN of_IN Ki_NNP 67_CD ,_, an_DT S-_NNP phase-associated_JJ nuclear_JJ antigen_NN ,_, was_VBD expressed_VBN in_IN the_DT majority_NN
          of_IN stage_NN 1_CD cells_NNS (_( see_VB Figure_NN 2_LS )_) ._. Genes_NNP specifying_VBG transcription_NN factors_NNS essential_JJ for_IN in_IN
          vivo_NN differentiation_NN of_IN lineage-restricted_JJ neural_NN progenitors_NNS and_CC their_PRP$ differentiated_JJ
          progeny_NN [_NN 21_CD ,_, 22_CD ,_, 23_CD ]_NN ,_, including_VBG 
          En_NNP 1_CD ,_, Hb_NNP 9_CD ,_, Isl_NNP 1_CD ,_, Hoxc_NNP 6_CD ,_, NRSF_NNP /_NN REST_NNP ,_, and_CC 
          Nkx_NNP 6_CD ._. 1_LS ,_, were_VBD expressed_VBN at_IN low_JJ or_CC undetectable_JJ levels_NNS in_IN stage_NN 1_CD (_( see_VB
          Figure_NN 1_CD B–_NNP 1_CD C_NNP )_) ,_, consistent_JJ with_IN the_DT reported_VBN multipotency_NN of_IN proliferating_VBG NSs_NNP grown_VBN in_IN
          high_JJ glucose_NN [_NN 14_CD ]_NN ._.
          After_IN 2_CD wk_NN at_IN stage_NN 2_CD ,_, NS-derived_NNP cells_NNS remained_VBD in_IN clusters_NNS (_( see_VB Figure_NN 1_CD A_DT )_) ,_, but_CC
          Nestin_NNP and_CC Ki_NNP 67_CD were_VBD expressed_VBN in_IN fewer_JJR than_IN 35_CD %_NN of_IN cells_NNS (_( see_VB Figure_NN 2_LS )_) ,_, indicating_VBG
          possible_JJ differentiation_NN of_IN cells_NNS toward_IN lineage-restricted_JJ fates_NNS ._. Consistent_NNP with_IN this_DT
          view_NN ,_, we_PRP detected_VBD increased_VBN expression_NN of_IN 
          Nkx_NNP 6_CD ._. 1_LS ,_, NRSF_NNP /_NN REST_NNP ,_, and_CC β-tubulin_JJ III_NNP (_( see_VB Figures_NNS 1_CD B_NNP and_CC 2_LS )_) ._. We_PRP also_RB
          detected_VBD increased_VBN expression_NN of_IN 
          Neurogenin_NNP 3_CD (_( ngn_NN 3_LS )_) (_( see_VB Figure_NN 1_CD C_NNP )_) ,_, a_DT transcription_NN factor_NN expressed_VBD in_IN
          differentiating_VBG neurons_NNS ,_, and_CC required_VBD for_IN development_NN of_IN pancreatic_JJ islet_NN progenitor_NN
          cells_NNS [_NN 24_CD ,_, 25_CD ,_, 26_CD ]_NN ._. 
          Nkx_NNP 6_CD ._. 1_LS and_CC 
          ngn_NN 3_CD expression_NN were_VBD never_RB observed_VBN in_IN NS_NNP cultures_NNS maintained_VBN in_IN 37_CD mM_NN
          glucose_NN (_( see_VB Figure_NN 1_CD B_NNP ;_: data_NNS not_RB shown_VBN )_) ._. These_DT data_NNS suggest_VBP that_DT glucose_NN restriction_NN
          initiates_NNS developmental_NN programs_NNS known_VBN to_TO promote_VB differentiation_NN of_IN mammalian_JJ neural_NN and_CC
          neuroendocrine_NN cells_NNS ._. As_IN shown_VBN below_IN ,_, insulin_NN expression_NN in_IN NS-derived_NNP cells_NNS required_VBD
          culture_NN in_IN low-glucose_JJ medium_NN at_IN stage_NN 2_CD ,_, but_CC we_PRP did_VBD not_RB consistently_RB detect_VB insulin_NN
          +_NN cells_NNS by_IN immunohistochemistry_NN until_IN stage_NN 4_CD ._.
        
        
          RA_NNP Promotes_NNP IPC_NNP Development_NNP
          RA_NNP induces_VBZ development_NN of_IN primitive_JJ endodermal_NN cells_NNS from_IN a_DT subset_NN of_IN embryonal_NN
          carcinoma_NN cell_NN lines_NNS ,_, and_CC is_VBZ an_DT endogenous_JJ signal_NN that_WDT directs_VBZ development_NN of_IN posterior_NN
          organs_NNS like_IN the_DT pancreas_NN from_IN embryonic_JJ endoderm_NN [_NN 27_CD ,_, 28_CD ]_NN ._. In_IN vivo_NN exposure_NN to_TO RA_NNP is_VBZ
          sufficient_JJ to_TO induce_VB ectopic_JJ development_NN of_IN insulin-expressing_JJ tissue_NN in_IN the_DT anterior_NN
          foregut_NN [_NN 27_CD ]_NN ._. Moreover_RB ,_, stage_NN 2_CD NS-derived_NNP cells_NNS expressed_VBD RA_NNP receptors_NNS including_VBG RAR-α_NNP
          and_CC RAR-γ_NNP (_( see_VB Figure_NN 1_CD C_NNP )_) ,_, indicating_VBG competence_NN for_IN RA_NNP signals_NNS ._. To_TO investigate_VB whether_IN
          RA_NNP could_MD stimulate_VB development_NN of_IN NS-derived_NNP cells_NNS toward_IN an_DT IPC_NNP fate_NN ,_, we_PRP measured_VBD
          expression_NN of_IN 
          Pdx_NNP 1_CD ,_, Cdx_NNP 1_CD ,_, and_CC 
          FoxA_NNP 3_CD ,_, transcription_NN factors_NNS that_WDT regulate_VB gastrointestinal_NN organ_NN
          development_NN [_NN 29_CD ,_, 30_CD ]_NN ._. 
          Pdx_NNP 1_CD ,_, Cdx_NNP 1_CD ,_, and_CC 
          FoxA_NNP 3_CD expression_NN was_VBD induced_VBN in_IN “ stage_NN 3_CD ,_,” when_WRB cell_NN clusters_NNS were_VBD
          allowed_VBN to_TO adhere_VB to_TO pre-coated_JJ wells_NNS at_IN a_DT density_NN of_IN 40_CD –_NN 80_CD NSs_NNP /_NN cm_NN
          2_CD and_CC cultured_JJ in_IN low-glucose_JJ medium_NN with_IN 2_CD μM_NN RA_NNP for_IN 2_CD wk_NN (_( see_VB Figure_NN
          1_CD A_DT and_CC 1_CD C_NNP )_) ._. We_PRP then_RB tested_VBD other_JJ concentrations_NNS of_IN RA_NNP and_CC other_JJ plating_VBG densities_NNS ._. NS_NNP
          cells_NNS exposed_VBN to_TO 100_CD nM_NN RA_NNP at_IN 20_CD ,_, 40_CD ,_, or_CC 80_CD NSs_NNP /_NN cm_NN
          2_CD and_CC NS_NNP cells_NNS exposed_VBN to_TO 2_CD μM_NN RA_NNP at_IN a_DT plating_VBG density_NN of_IN 20_CD NSs_NNP /_NN cm_NN
          2_CD did_VBD not_RB express_VB these_DT markers_NNS or_CC insulin_NN at_IN a_DT later_JJ stage_NN (_(“ stage_NN
          4_CD” ;_: Figure_NN 3_CD A_DT ;_: data_NN not_RB shown_VBN )_) ._. Thus_RB ,_, higher_JJR doses_NNS of_IN RA_NNP induced_VBD markers_NNS of_IN posterior_NN
          fate_NN in_IN NS-derived_NNP cells_NNS ,_, a_DT dosage_NN response_NN like_IN that_DT seen_VBN during_IN RA_NNP patterning_VBG of_IN
          posterior_NN gut_NN development_NN in_IN vivo_NN ._. Moreover_RB ,_, this_DT response_NN was_VBD sensitive_JJ to_TO plating_VBG
          density_NN ,_, revealing_VBG that_IN additional_JJ cell-non-autonomous_JJ factors_NNS may_MD regulate_VB this_DT
          response_NN ._. Mesoderm_NNP develops_VBZ in_IN close_JJ association_NN with_IN gastrointestinal_NN endoderm_NN both_DT in_IN
          vivo_NN and_CC in_IN vitro_NN [_NN 31_CD ,_, 32_CD ]_NN ._. Thus_RB ,_, detection_NN of_IN gut_NN markers_NNS like_IN 
          Pdx_NNP 1_CD and_CC 
          FoxA_NNP 3_CD in_IN NS-derived_NNP cell_NN cultures_NNS raised_VBD the_DT possibility_NN that_IN
          mesodermal_NN cells_NNS might_MD co-develop_JJ ._. However_RB ,_, we_PRP did_VBD not_RB detect_VB expression_NN of_IN known_VBN markers_NNS
          of_IN mesoderm_NN formation_NN ,_, including_VBG 
          brachyury_NN ,_, flk-_NN 1_CD ,_, myosin_NN light_JJ chain-_NN 2_CD ,_, and_CC 
          β-globin_JJ ,_, at_IN any_DT stage_NN in_IN our_PRP$ cultures_NNS (_( see_VB Figure_NN 1_CD B_NNP )_) ._. By_IN contrast_NN ,_,
          mesoderm_NN development_NN invariably_RB accompanies_VBZ endoderm_NN development_NN in_IN embryoid_NN bodies_NNS
          derived_VBN from_IN human_JJ ES_NNP cells_NNS or_CC embryonic_JJ germ_NN cells_NNS [_NN 31_CD ,_, 32_CD ,_, 33_CD ]_NN ._. In_IN stage_NN 3_CD cultures_NNS ,_,
          Nestin_NNP and_CC Ki_NNP 67_CD expression_NN was_VBD nearly_RB extinguished_JJ (_( see_VB Figure_NN 2_LS )_) ,_, while_IN expression_NN of_IN 
          En_NNP 1_CD ,_, ngn_NN 3_CD ,_, and_CC 
          Hb_NNP 9_CD increased_VBN (_( see_VB Figure_NN 1_CD B_NNP and_CC 1_CD C_NNP )_) ._. While_IN their_PRP$ numbers_NNS increased_VBN
          slightly_RB during_IN stage_NN 3_CD ,_, β-tubulin_JJ III_NNP
          +_NN cells_NNS composed_VBN fewer_JJR than_IN 10_CD %_NN of_IN cells_NNS in_IN NS-derived_NNP clusters_NNS (_( see_VB
          Figure_NN 2_LS )_) ,_, suggesting_VBG that_IN the_DT majority_NN of_IN differentiated_JJ cells_NNS had_VBD acquired_VBN non-neural_JJ
          fates_NNS ._. Consistent_NNP with_IN this_DT interpretation_NN ,_, we_PRP also_RB did_VBD not_RB detect_VB expression_NN of_IN
          homeodomain_NN proteins_NNS Hoxc_NNP 6_CD or_CC Hoxb_NNP 9_CD (_( see_VB Figure_NN 1_CD B_NNP ;_: data_NNS not_RB shown_VBN )_) ,_, which_WDT are_VBP induced_VBN by_IN
          RA_NNP in_IN spinal_JJ cord_NN neuronal_NN precursor_NN cells_NNS [_NN 21_CD ]_NN ._.
          RA_NNP can_MD activate_VBP signaling_VBG through_IN the_DT Hedgehog_NNP (_( Hh_NNP )_) pathway_NN ,_, and_CC recent_JJ studies_NNS show_VBP
          that_IN Hh_NNP signals_NNS control_VBP development_NN of_IN embryonic_JJ pancreatic_JJ islets_NNS in_IN vivo_NN [_NN 16_CD ,_, 34_CD ]_NN ._. To_TO
          elucidate_NN the_DT mechanisms_NNS underlying_VBG RA-induced_NNP expression_NN of_IN markers_NNS like_IN 
          FoxA_NNP 3_CD and_CC 
          Pdx_NNP 1_CD ,_, we_PRP examined_VBD Hh_NNP signaling_VBG during_IN IPC_NNP development_NN ._. We_PRP detected_VBD
          expression_NN of_IN the_DT Hedgehog_NNP receptors_NNS 
          Patched_NNP (_( Ptc_NNP )_) and_CC 
          Smoothened_NNP (_( Smo_NNP )_) at_IN all_DT stages_NNS (_( Figure_NN 3_CD B_NNP )_) ,_, consistent_JJ with_IN the_DT
          possibility_NN that_IN NS-derived_NNP cells_NNS are_VBP competent_JJ for_IN Hh_NNP signaling_VBG ._. However_RB ,_, we_PRP did_VBD not_RB
          detect_VB NS_NNP expression_NN of_IN genes_NNS encoding_VBG Hh_NNP ligands_NNS like_IN 
          Shh_NNP (_( Figure_NN 3_CD B_NNP )_) ,_, similar_JJ to_TO previous_JJ studies_NNS [_NN 19_CD ]_NN ._. Increased_VBN 
          Ptc_NNP transcription_NN is_VBZ a_DT known_VBN consequence_NN of_IN Shh_NNP signaling_VBG ,_, but_CC we_PRP did_VBD
          not_RB detect_VB changes_NNS of_IN 
          Ptc_NNP expression_NN during_IN stages_NNS 1_CD –_NN 4_CD ,_, consistent_JJ with_IN the_DT absence_NN of_IN
          detectable_JJ expression_NN of_IN Hh_NNP ligands_NNS ._. To_TO test_VB directly_RB whether_IN the_DT absence_NN of_IN Hh_NNP signaling_VBG
          was_VBD required_VBN for_IN expression_NN of_IN endodermal_NN or_CC islet_NN markers_NNS ,_, including_VBG 
          FoxA_NNP 3_CD ,_, Pdx_NNP 1_CD ,_, and_CC insulin_NN ,_, we_PRP added_VBD Shh_NNP protein_NN to_TO stage_VB 4_CD cultures_NNS ,_,
          which_WDT do_VBP not_RB express_VB 
          Shh_NNP or_CC genes_NNS encoding_VBG other_JJ Hh_NNP ligands_NNS like_IN 
          Desert_NNP hedgehog_NN or_CC 
          Indian_JJ hedgehog_NN (_( Figure_NN 3_CD C_NNP )_) ._. At_IN 300_CD nM_NN ,_, a_DT dose_NN used_VBN to_TO induce_VB
          neuronal_NN development_NN in_IN ES_NNP cell_NN cultures_NNS [_NN 21_CD ]_NN ,_, Shh_NNP produced_VBD a_DT significant_JJ increase_NN in_IN
          neurite_NN outgrowth_NN in_IN NS-derived_NNP cells_NNS (_( Figure_NN 3_CD D_NNP and_CC 3_CD E_NNP ;_: see_VB Methods_NNP )_) ,_, and_CC resulted_VBD in_IN
          increased_VBN 
          Ptc_NNP expression_NN (_( Figure_NN 3_CD F_NN )_) ._. Moreover_RB ,_, Shh_NNP treatment_NN during_IN stage_NN 4_CD
          eliminated_VBN expression_NN of_IN 
          Pdx_NNP 1_CD ,_, FoxA_NNP 3_CD ,_, and_CC insulin_NN (_( Figure_NN 3_CD F_NN )_) ._. These_DT data_NNS are_VBP reminiscent_NN of_IN
          prior_JJ studies_VBZ demonstrating_VBG that_IN excess_JJ endodermal_NN Shh_NNP signaling_VBG disrupts_NNS pancreas_NN
          development_NN in_IN vivo_NN [_NN 16_CD ,_, 34_CD ]_NN ._. Thus_RB ,_, in_IN contrast_NN to_TO the_DT response_NN of_IN ES_NNP cells_NNS [_NN 21_CD ]_NN ,_, RA_NNP
          treatment_NN of_IN NS-derived_NNP cells_NNS does_VBZ not_RB stimulate_VB endogenous_JJ Hh_NNP signaling_VBG ._. The_DT lack_NN of_IN Hh_NNP
          signals_NNS in_IN NS-derived_NNP cells_NNS blunts_NNS neural_NN differentiation_NN and_CC permits_VBZ differentiation_NN
          toward_IN endocrine-like_JJ cell_NN fates_NNS ._.
        
        
          Insulin_NNP Expression_NNP by_IN IPCs_NNP
          
          ngn_NN 3_CD ,_, Pdx_NNP 1_CD ,_, and_CC 
          Hb_NNP 9_CD are_VBP essential_JJ factors_NNS for_IN mammalian_JJ β-cell_JJ development_NN [_NN 22_CD ]_NN ,_, and_CC
          their_PRP$ expression_NN in_IN stage_NN 3_CD suggested_VBD the_DT potential_NN for_IN deriving_VBG IPCs_NNP ._. Insulin_NNP expression_NN
          has_VBZ not_RB ,_, to_TO our_PRP$ knowledge_NN ,_, been_VBN reported_VBN in_IN NS-derived_NNP cells_NNS [_NN 19_CD ,_, 35_CD ]_NN ._. Moderate_NNP
          hyperglycemia_NN is_VBZ a_DT potent_JJ stimulus_NN for_IN β-cell_JJ differentiation_NN and_CC expansion_NN in_IN vivo_NN and_CC
          in_IN utero_NN [_NN 20_CD ]_NN ,_, so_IN we_PRP tested_VBD whether_IN exposure_NN of_IN stage_NN 3_CD cells_NNS to_TO elevated_VBD glucose_NN levels_NNS
          could_MD induce_VB insulin_NN expression_NN ._. Semi-quantitative_NNP RT-PCR_NNP measures_NNS of_IN insulin_NN mRNA_NN
          expression_NN showed_VBD that_DT exposure_NN of_IN cultures_NNS grown_VBN in_IN 5_CD mM_NN glucose_NN at_IN stage_NN 3_CD to_TO 17_CD mM_NN
          glucose_NN at_IN stage_NN 4_CD induced_VBN insulin_NN expression_NN (_( Figure_NN 3_CD A_DT )_) ._. Growth_NN of_IN cells_NNS at_IN stage_NN 2_CD in_IN
          5_CD mM_NN glucose_NN followed_VBN by_IN exposure_NN in_IN stages_NNS 3_CD and_CC 4_CD to_TO 17_CD mM_NN glucose_NN also_RB resulted_VBD in_IN
          insulin_NN expression_NN at_IN stage_NN 4_CD ,_, but_CC at_IN lower_JJR levels_NNS ._. By_IN contrast_NN ,_, no_DT insulin_NN was_VBD expressed_VBN
          by_IN cultures_NNS maintained_VBN in_IN 5_CD mM_NN glucose_NN or_CC 17_CD mM_NN glucose_NN throughout_IN stages_NNS 2_CD –_NN 4_CD (_( Figure_NN
          3_CD A_DT )_) ._. Thus_RB ,_, reduction_NN of_IN glucose_NN in_IN stage_NN 2_CD growth_NN medium_NN followed_VBN by_IN a_DT later_JJ increase_NN in_IN
          glucose_NN at_IN stage_NN 3_CD or_CC 4_CD was_VBD essential_JJ for_IN development_NN of_IN IPCs_NNP ._. Insulin-like_NNP growth_NN
          factor-_NN 1_CD may_MD promote_VB insulin_NN secretion_NN and_CC prevent_VB apoptosis_NNS of_IN β-cells_JJ in_IN vivo_NN [_NN 36_CD ]_NN ,_, and_CC
          addition_NN of_IN this_DT factor_NN at_IN stage_NN 4_CD reduced_VBN apoptosis_NNS approximately_RB 10_CD -_: fold_VB (_( see_VB Figure_NN
          1_CD A_DT ;_: data_NN not_RB shown_VBN )_) ._. Nicotinamide_NNP ,_, which_WDT can_MD stimulate_VB in_IN vivo_NN pancreatic_JJ endocrine_NN cell_NN
          differentiation_NN [_NN 37_CD ]_NN ,_, did_VBD not_RB affect_VB cell_NN survival_NN ,_, but_CC did_VBD increase_NN insulin_NN C-_NNP peptide_NN
          expression_NN approximately_RB 1_CD ._. 5_CD -_: to_TO 2_CD -_: fold_VB (_( data_NNS not_RB shown_VBN )_) ._. Thus_RB ,_, simultaneous_JJ exposure_NN to_TO
          high_JJ glucose_NN levels_NNS ,_, insulin-like_JJ growth_NN factor-_NN 1_CD ,_, and_CC nicotinamide_NN optimized_JJ insulin_NN
          expression_NN at_IN stage_NN 4_CD ._. Comparable_JJ results_NNS were_VBD obtained_VBN with_IN three_CD independently_RB derived_VBN
          NS_NNP lines_NNS ._.
          Coinciding_NNP with_IN the_DT onset_NN of_IN high_JJ insulin_NN expression_NN levels_NNS in_IN mouse_NN islets_NNS ,_, 
          ngn_NN 3_CD expression_NN is_VBZ virtually_RB extinguished_JJ [_NN 25_CD ]_NN ,_, while_IN expression_NN of_IN 
          Pdx_NNP 1_CD ,_, FoxA_NNP 3_CD ,_, Isl_NNP 1_CD ,_, and_CC 
          Nkx_NNP 6_CD ._. 1_LS in_IN islet_NN β-cells_JJ is_VBZ maintained_VBN or_CC increased_VBN [_NN 22_CD ]_NN ._. Similarly_RB ,_, we_PRP
          noted_VBD that_IN IPC_NNP maturation_NN from_IN stage_NN 3_CD to_TO 4_CD was_VBD accompanied_VBN by_IN increased_VBN insulin_NN
          expression_NN ,_, reduced_VBN 
          ngn_NN 3_CD expression_NN ,_, and_CC increased_VBD or_CC maintained_VBN levels_NNS of_IN 
          Isl_NNP 1_CD ,_, FoxA_NNP 3_CD ,_, and_CC 
          Pdx_NNP 1_CD expression_NN (_( see_VB Figure_NN 1_CD B_NNP and_CC 1_CD C_NNP )_) ._. Thus_RB ,_, tissues_NNS derived_VBN from_IN
          neural_NN progenitor_NN cells_NNS express_VBP insulin_NN ,_, 
          Pdx_NNP 1_CD ,_, and_CC 
          FoxA_NNP 3_CD ,_, markers_NNS typically_RB co-expressed_JJ in_IN foregut-derived_JJ tissues_NNS ._.
          Expression_NNP of_IN these_DT markers_NNS suggests_VBZ differentiation_NN of_IN some_DT neural_NN progenitor_NN cells_NNS
          toward_IN an_DT endoderm-like_JJ fate_NN ._. We_PRP were_VBD unable_JJ to_TO detect_VB expression_NN of_IN Pdx_NNP 1_CD and_CC FoxA_NNP 3_CD using_VBG
          immunohistochemical_JJ methods_NNS in_IN stage_NN 4_CD IPCs_NNP ,_, (_( data_NNS not_RB shown_VBN )_) ._. We_PRP also_RB did_VBD not_RB detect_VB
          expression_NN of_IN Nkx_NNP 6_CD ._. 1_LS or_CC islet_NN amyloid_NN polypeptide_NN ,_, markers_NNS of_IN mature_VBP pancreatic_JJ β-cells_JJ
          (_( see_VB Figure_NN 1_CD C_NNP ;_: data_NNS not_RB shown_VBN )_) ._. Thus_RB ,_, the_DT sequence_NN of_IN gene_NN expression_NN accompanying_VBG
          formation_NN of_IN IPCs_NNP from_IN NSs_NNP was_VBD similar_JJ but_CC not_RB identical_JJ to_TO that_DT described_VBD for_IN
          differentiating_VBG pancreatic_JJ β-cells_JJ ,_, and_CC further_JJ molecular_JJ studies_NNS are_VBP required_VBN to_TO
          determine_VB the_DT degree_NN of_IN endoderm-like_JJ differentiation_NN of_IN cells_NNS in_IN IPCs_NNP ._.
          We_PRP detected_VBD expression_NN of_IN insulin_NN protein_NN by_IN immunohistochemistry_NN in_IN 90_CD %_NN of_IN stage_NN 4_CD
          cell_NN clusters_NNS (_( Figure_NN 4_LS )_) ._. An_DT average_NN of_IN 26_CD %_NN of_IN cells_NNS in_IN stage_NN 4_CD clusters_NNS were_VBD insulin_NN
          +_NN ,_, and_CC appeared_VBD healthy_JJ ,_, with_IN abundant_JJ cytoplasm_NN and_CC a_DT well-defined_JJ
          nucleus_NN delineated_JJ by_IN the_DT nuclear_JJ stain_VB 7_CD AAD_NNP (_( Figure_NN 4_CD A_DT )_) ._. Of_IN the_DT cells_NNS composing_VBG stage_NN 4_CD
          clusters_NNS ,_, 45_CD %_NN were_VBD β-tubulin_JJ III_NNP
          +_NN ,_, none_NN of_IN which_WDT contained_VBD insulin_NN (_( Figure_NN 5_CD A–_NNP 5_CD C_NNP )_) ._. Insulin_NNP
          +_NN cells_NNS showed_VBD little_JJ or_CC no_DT co-expression_JJ of_IN neural_NN stem_NN cell_NN markers_NNS
          like_IN Nestin_NNP (_( see_VB Figure_NN 1_LS )_) ,_, or_CC other_JJ markers_NNS of_IN neural_NN lineages_NNS known_VBN to_TO develop_VB from_IN
          human_JJ neural_NN progenitors_NNS ,_, like_IN MAP_NNP 2_CD (_( differentiated_JJ neurons_NNS ;_: Figure_NN 5_CD D–_NNP 5_CD F_NN )_) ,_, Olig_NNP 2_CD
          (_( multipotent_NN precursors_NNS ,_, bipotent_NN glial_NN precursors_NNS ,_, and_CC oligodendrocytes_NNS ;_: Figure_NN 5_CD J–_NNP 5_CD L_NNP ;_:
          see_VB [_NN 38_CD ]_NN )_) ,_, or_CC myelin_NN basic_JJ protein_NN (_( data_NNS not_RB shown_VBN )_) ._. Occasional_NNP rare_JJ insulin_NN
          +_NN cells_NNS expressed_VBD detectable_JJ GFAP_NNP (_( a_DT marker_NN of_IN astrocytes_NNS ;_: Figure_NN
          5_CD G–_NNP 5_CD I_PRP )_) ._. Thus_RB ,_, while_IN we_PRP cannot_NN completely_RB rule_NN out_RP the_DT possibility_NN that_IN some_DT neural_NN cell_NN
          types_NNS expressed_VBD insulin_NN ,_, these_DT data_NNS suggest_VBP that_IN nearly_RB all_DT insulin_NN
          +_NN cells_NNS produced_VBN in_IN stage_NN 4_CD cultures_NNS were_VBD non-neuronal_JJ ._.
          Nuclei_NNP in_IN insulin_NN
          +_NN cells_NNS were_VBD not_RB stained_JJ by_IN an_DT antibody_NN to_TO Ki_NNP 67_CD (_( see_VB Figures_NNS 2_CD and_CC
          4_CD B_NNP )_) ,_, suggesting_VBG that_DT insulin_NN
          +_NN cells_NNS at_IN stage_NN 4_CD are_VBP post-mitotic_JJ ,_, like_IN mature_VBP pancreatic_JJ β-cells_JJ ._.
          Immunostaining_NNP with_IN specific_JJ antibodies_NNS revealed_VBD proinsulin_NN and_CC C-_NNP peptide_NN ,_, an_DT internal_JJ
          portion_NN of_IN the_DT proinsulin_NN translation_NN product_NN ,_, in_IN the_DT cytoplasm_NN of_IN all_DT insulin_NN
          +_NN cells_NNS (_( see_VB Figure_NN 4_CD D–_NNP 4_CD G_NNP and_CC 4_CD O_NNP )_) ,_, supporting_VBG our_PRP$ conclusion_NN that_DT
          insulin_NN protein_NN was_VBD produced_VBN in_IN stage_NN 4_CD IPCs_NNP ._. In_IN situ_NN hybridization_NN with_IN antisense_NN
          riboprobes_NNS specific_JJ for_IN human_JJ insulin_NN mRNA_NN labeled_VBD 25_CD %_NN –_NN 30_CD %_NN of_IN stage_NN 4_CD cells_NNS (_( see_VB Figure_NN
          4_CD H–_NNP 4_CD J_NNP )_) ,_, providing_VBG further_JJ evidence_NN of_IN insulin_NN production_NN ._. We_PRP observed_VBD only_RB rare_JJ insulin_NN
          +_NN cells_NNS stained_JJ by_IN antibodies_NNS specific_JJ for_IN activated_VBN caspase-_NN 3_CD
          (_( <_NN 0_CD ._. 3_LS %_NN ;_: see_VB Figure_NN 4_CD K_NNP )_) or_CC TUNEL_NNP assay_NN (_( data_NNS not_RB shown_VBN )_) ._. In_IN stage_NN 4_CD cell_NN clusters_NNS we_PRP
          did_VBD not_RB consistently_RB detect_VB expression_NN of_IN glucagon_NN (_( see_VB Figure_NN 4_CD L_NNP )_) ,_, pancreatic_JJ
          polypeptide_NN ,_, or_CC somatostatin_NN by_IN immunohistochemistry_NN ._. The_DT absence_NN of_IN glucagon_NN gene_NN
          expression_NN in_IN our_PRP$ IPC_NNP cultures_NNS was_VBD further_RBR confirmed_VBN by_IN RT-PCR_NNP (_( data_NNS not_RB shown_VBN )_) ._. Thus_RB ,_,
          like_IN in_IN pancreatic_JJ islets_NNS ,_, insulin_NN was_VBD the_DT principal_JJ hormone_NN produced_VBN by_IN IPCs_NNP ._. However_RB ,_,
          the_DT composition_NN of_IN IPCs_NNP was_VBD distinct_JJ from_IN that_DT of_IN pancreatic_JJ islets_NNS ,_, and_CC further_JJ studies_NNS
          are_VBP required_VBN to_TO determine_VB the_DT basis_NN for_IN this_DT difference_NN ._.
          To_TO quantify_VB insulin_NN expression_NN in_IN IPCs_NNP ,_, we_PRP used_VBD a_DT human_JJ insulin_NN C-_NNP peptide-specific_JJ
          ELISA_NNP (_( see_VB Figure_NN 4_CD P_NN )_) ._. By_IN ELISA_NNP ,_, we_PRP did_VBD not_RB detect_VB C-_NNP peptide_NN in_IN stage_NN 3_CD or_CC stage_NN 4_CD
          culture_NN media_NNS ,_, which_WDT contained_VBD supplementary_JJ bovine_JJ insulin_NN ._. Thus_RB ,_, use_NN of_IN a_DT C-_NNP peptide_NN
          assay_NN did_VBD not_RB detect_VB medium-derived_JJ bovine_JJ insulin_NN in_IN measures_NNS of_IN IPC_NNP insulin_NN content_NN
          [_NN 39_CD ]_NN ._. C-_NNP peptide_NN levels_NNS at_IN stages_NNS 1_CD –_NN 3_CD were_VBD low_JJ or_CC undetectable_JJ (_( see_VB Figure_NN 4_CD P_NN )_) ,_, consistent_JJ
          with_IN the_DT lack_NN of_IN immunostainable_JJ insulin_NN (_( see_VB Figure_NN 2_LS )_) in_IN cells_NNS at_IN these_DT earlier_JJR stages_NNS ._.
          Similarly_RB ,_, in_IN cultures_NNS maintained_VBN in_IN 17_CD mM_NN glucose_NN during_IN stages_NNS 1_CD –_NN 4_CD (_(“ HHHH_NNP” )_) ,_, C-_NNP peptide_NN
          levels_NNS were_VBD not_RB detectable_JJ (_( see_VB Figure_NN 4_CD P_NN )_) ._. In_IN cell_NN clusters_NNS exposed_VBN to_TO 5_CD mM_NN glucose_NN in_IN
          stages_NNS 2_CD –_NN 3_CD then_RB switched_VBD to_TO 17_CD mM_NN glucose_NN at_IN stage_NN 4_CD (_(“ HLLH_NNP” )_) ,_, insulin_NN C-_NNP peptide_NN levels_NNS
          were_VBD 0_CD ._. 36_CD fmol_NN per_IN cluster_NN ,_, and_CC the_DT average_JJ number_NN of_IN C-_NNP peptide_NN
          +_NN cells_NNS per_IN cluster_NN was_VBD 200_CD ._. Thus_RB ,_, we_PRP estimate_VBP 0_CD ._. 0018_CD fmol_NN C-_NNP peptide_NN
          per_IN NS-derived_NNP IPC_NNP ._. A_DT single_JJ β-cell_JJ contains_VBZ approximately_RB 0_CD ._. 6_CD fmol_NN C-_NNP peptide_NN and_CC insulin_NN
          [_NN 40_CD ]_NN ,_, so_IN we_PRP calculate_VBP that_DT insulin_NN C-_NNP peptide_NN content_NN in_IN one_CD stage_NN 4_CD IPC_NNP is_VBZ approximately_RB
          0_CD ._. 3_CD %_NN of_IN the_DT level_NN in_IN isolated_VBN human_JJ β-cells_JJ ._. Collectively_RB ,_, these_DT experiments_NNS confirm_VBP that_IN
          IPCs_NNP transcribe_VBP and_CC translate_VB insulin_NN ,_, and_CC rule_NN out_IN that_IN insulin_NN measured_VBN in_IN IPCs_NNP is_VBZ
          derived_VBN from_IN medium_NN ,_, as_IN shown_VBN in_IN another_DT system_NN [_NN 39_CD ]_NN ._.
        
        
          IPCs_NNP Are_VBP Glucose_NNP Responsive_NNP
          Glucokinase_NNP and_CC glucose_NN transporters_NNS like_IN Glut-_NNP 2_CD are_VBP essential_JJ regulators_NNS of_IN glucose_NN
          responses_NNS in_IN pancreatic_JJ β-cells_JJ ,_, and_CC expression_NN of_IN these_DT regulators_NNS in_IN stage_NN 4_CD insulin_NN
          +_NN cells_NNS (_( see_VB Figures_NNS 1_CD C_NNP ,_, 4_CD M_NNP ,_, and_CC 4_CD N_NNP )_) suggested_VBD that_IN IPCs_NNP could_MD sense_VB
          and_CC respond_VB to_TO glucose_NN ._. To_TO test_VB whether_IN IPCs_NNP respond_VB appropriately_RB to_TO glucose_NN
          stimulation_NN ,_, we_PRP measured_VBD insulin_NN release_NN in_IN static_JJ batch_NN in_IN vitro_NN assays_NNS ._. We_PRP found_VBD that_IN
          IPC_NNP insulin_NN release_NN increased_VBD markedly_RB following_VBG a_DT step_NN increase_NN of_IN glucose_NN from_IN 2_CD ._. 8_CD to_TO
          25_CD mM_NN (_( see_VB Figure_NN 4_CD Q_NNP )_) ._. To_TO examine_VB whether_IN IPCs_NNP are_VBP similarly_RB responsive_JJ to_TO glucose_NN
          stimulation_NN in_IN vivo_NN ,_, we_PRP performed_VBD a_DT series_NN of_IN IPC_NNP grafting_VBG experiments_NNS in_IN
          immunocompromised_JJ recipient_JJ mice_NNS ._. Two_CD weeks_NNS following_VBG engraftment_NN (_( 1_CD ,_, 000_CD IPC-containing_NNP
          clusters_NNS /_NN mouse_NN )_) ,_, recipient_JJ mice_NNS and_CC sham-transplanted_JJ controls_NNS were_VBD fasted_JJ overnight_JJ ,_, and_CC
          human_JJ C-_NNP peptide_NN levels_NNS measured_VBN ._. Human_NNP C-_NNP peptide_NN was_VBD undetectable_JJ in_IN mouse_NN sera_NN prior_RB to_TO
          glucose_NN challenge_NN ,_, or_CC following_VBG glucose_NN challenge_NN of_IN sham-transplanted_JJ controls_NNS (_( see_VB
          Figure_NN 4_CD R_NN )_) ._. In_IN contrast_NN ,_, 30_CD min_NN after_IN intraperitoneal_NN glucose_NN challenge_NN of_IN IPC_NNP recipients_NNS
          we_PRP detected_VBD 6_CD ._. 1_CD ±_NN 1_CD ._. 2_CD pmol_NN /_NN l_NN human_JJ C-_NNP peptide_NN (_(
          p_NN <_NN 0_CD ._. 001_CD )_) ,_, approximately_RB 0_CD ._. 5_CD %_NN –_NN 1_CD %_NN of_IN serum_NN C-_NNP peptide_NN levels_NNS observed_VBD
          following_VBG engraftment_NN of_IN 2_CD ,_, 000_CD human_JJ islet_NN equivalents_NNS in_IN a_DT prior_JJ study_NN [_NN 41_CD ]_NN ._. Thus_RB ,_, IPCs_NNP
          respond_VBP to_TO glucose_NN challenge_NN in_IN vivo_NN by_IN releasing_VBG insulin_NN C-_NNP peptide_NN ._. Analysis_NNP of_IN IPC_NNP
          graft_NN sites_NNS 4_CD wk_NN after_IN transplantation_NN revealed_VBD nests_NNS of_IN transplanted_VBN cells_NNS without_IN
          obvious_JJ tumor_NN formation_NN ._. Histologic_NNP analysis_NN and_CC immunohistochemical_JJ detection_NN revealed_VBD
          that_IN C-_NNP peptide-expressing_JJ cells_NNS persisted_VBD in_IN the_DT graft_NN site_NN (_( see_VB Figure_NN 4_CD S_NNP and_CC 4_CD T_NN )_) ._. Thus_RB ,_,
          engrafted_JJ IPCs_NNP remained_VBD differentiated_JJ and_CC survived_VBD up_IN to_TO a_DT month_NN following_VBG
          transplantation_NN ._.
        
      
      
        Discussion_NNP
        There_EX is_VBZ widespread_JJ interest_NN in_IN developing_VBG tissue_NN replacement_NN strategies_NNS for_IN treatment_NN
        of_IN human_JJ disorders_NNS like_IN diabetes_NN mellitus_JJ and_CC Parkinson_NNP disease_NN ._. While_IN much_JJ attention_NN has_VBZ
        been_VBN focused_VBN on_IN the_DT promise_NN of_IN ES_NNP cells_NNS for_IN tissue_NN replacement_NN ,_, recent_JJ work_NN suggests_VBZ that_DT
        neural_NN stem_NN cells_NNS ,_, like_IN ES_NNP cells_NNS ,_, may_MD have_VB an_DT unusually_RB broad_JJ differentiation_NN potential_JJ ._.
        For_IN example_NN ,_, Gage_NNP and_CC colleagues_NNS demonstrated_VBD the_DT conversion_NN of_IN mouse_NN neural_NN stem_NN cells_NNS to_TO
        the_DT endothelial_NN lineage_NN ,_, indicating_VBG that_DT plasticity_NN is_VBZ a_DT bona_JJ fide_JJ property_NN of_IN cultured_JJ
        neural_NN stem_NN cells_NNS [_NN 42_CD ]_NN ._. These_DT results_NNS were_VBD also_RB unexpected_JJ because_IN endothelial_NN cells_NNS and_CC
        neuronal_NN cells_NNS normally_RB derive_VB ,_, respectively_RB ,_, from_IN mesoderm_NN and_CC ectoderm_NN ,_, distinct_JJ
        embryonic_JJ germ_NN layers_NNS ._. Here_RB we_PRP show_VBP that_IN human_JJ neural_NN stem_NN cells_NNS have_VBP a_DT similarly_RB broad_JJ
        differentiation_NN potential_JJ ,_, and_CC that_IN specific_JJ in_IN vitro_NN culture_NN conditions_NNS can_MD divert_VB neural_NN
        stem-derived_JJ cells_NNS from_IN neural_NN lineages_NNS toward_IN a_DT fate_NN with_IN endocrine_NN and_CC endodermal_NN
        characteristics_NNS ._.
        Our_PRP$ study_NN shows_VBZ that_DT application_NN of_IN endogenous_JJ signals_NNS governing_VBG pancreas_NN development_NN to_TO
        human_JJ neural_NN progenitor_NN cells_NNS can_MD generate_VB glucose-responsive_JJ IPCs_NNP ._. Systematic_NNP variation_NN of_IN
        the_DT identity_NN ,_, concentration_NN ,_, and_CC sequence_NN of_IN these_DT signals_NNS led_VBN to_TO discovery_NN of_IN methods_NNS
        culminating_VBG in_IN IPC_NNP formation_NN ._. However_RB ,_, there_EX are_VBP limitations_NNS to_TO our_PRP$ findings_NNS that_WDT should_MD be_VB
        noted_VBN ._. First_LS ,_, our_PRP$ molecular_JJ analysis_NN of_IN differentiating_VBG IPCs_NNP showed_VBD that_IN they_PRP remain_VBP
        distinct_JJ from_IN mature_VBP pancreatic_JJ islet_NN β-cells_JJ ;_: in_IN other_JJ words_NNS ,_, the_DT insulin_NN
        +_NN cells_NNS derived_VBN by_IN our_PRP$ methods_NNS are_VBP not_RB mature_VB β-cells_JJ ._. For_IN example_NN ,_,
        reverse_VB transcriptase_NN polymerase_NN chain_NN reaction_NN confirmed_VBD that_IN IPCs_NNP were_VBD enriched_JJ for_IN a_DT
        combination_NN of_IN gene_NN products_NNS that_IN approximate_JJ those_DT expressed_VBD in_IN developing_VBG pancreatic_JJ
        islet_NN cells_NNS ._. However_RB ,_, the_DT temporal_JJ sequence_NN of_IN expression_NN of_IN some_DT of_IN these_DT products_NNS ,_, like_IN
        glucokinase_NN ,_, Glut-_NNP 2_CD ,_, and_CC Pdx_NNP 1_CD does_VBZ not_RB precisely_RB recapitulate_NN that_WDT observed_VBD in_IN the_DT
        embryonic_JJ pancreas_NN (_( reviewed_VBN in_IN [_NN 22_CD ]_NN )_) ,_, and_CC transcription_NN of_IN other_JJ genes_NNS typically_RB expressed_VBD
        in_IN β-cells_JJ ,_, like_IN 
        Nkx_NNP 6_CD ._. 1_LS ,_, was_VBD not_RB detected_VBN in_IN later_RB stage_NN IPCs_NNP (_( see_VB Figure_NN 1_LS )_) ._. Thus_RB ,_, the_DT
        insulin_NN
        +_NN cells_NNS derived_VBN in_IN this_DT study_NN are_VBP not_RB bona_JJ fide_JJ β-cells_JJ ._. Further_RB
        experimentation_NN may_MD elucidate_NN the_DT basis_NN for_IN these_DT differences_NNS ,_, revealing_VBG the_DT extent_NN of_IN
        neural_NN progenitor_NN cell_NN development_NN toward_IN an_DT endocrine_NN cell_NN fate_NN ._. Recent_JJ studies_NNS suggest_VBP
        that_IN neural_NN cells_NNS can_MD be_VB derived_VBN from_IN adult_NN pancreatic_JJ epithelium_NN [_NN 7_CD ,_, 8_CD ]_NN ,_, adding_VBG to_TO a_DT
        growing_VBG body_NN of_IN data_NNS demonstrating_VBG numerous_JJ similarities_NNS in_IN neural_NN and_CC pancreatic_JJ endocrine_NN
        development_NN (_( reviewed_VBN in_IN [_NN 43_CD ]_NN )_) ._. In_IN light_NN of_IN these_DT similarities_NNS ,_, we_PRP speculate_VBP that_IN methods_NNS
        leading_VBG to_TO the_DT production_NN of_IN β-cell_JJ factors_NNS like_IN Nkx_NNP 6_CD ._. 1_LS in_IN stage_NN 4_CD clusters_NNS may_MD enhance_VB the_DT
        β-cell-like_JJ qualities_NNS of_IN neural-progenitor-derived_JJ insulin_NN
        +_NN cells_NNS ,_, and_CC thereby_RB permit_VB differentiation_NN of_IN tissues_NNS that_IN more_RBR closely_RB
        resemble_VB endoderm-derived_JJ islet_NN cells_NNS ._. Second_JJ ,_, our_PRP$ immunohistochemical_JJ analysis_NN shows_VBZ that_DT
        stage_NN 4_CD insulin-expressing_JJ cells_NNS do_VBP not_RB express_VB markers_NNS like_IN Nestin_NNP ,_, β-tubulin_JJ III_NNP ,_, MAP_NNP 2_CD ,_,
        or_CC Olig_NNP 2_CD ,_, suggesting_VBG that_IN these_DT insulin_NN
        +_NN cells_NNS are_VBP non-neuronal_JJ ,_, but_CC we_PRP cannot_NN formally_RB rule_NN out_RP the_DT alternate_JJ
        possibility_NN that_IN our_PRP$ methods_NNS produced_VBD neural_NN cells_NNS capable_JJ of_IN secreting_VBG insulin_NN ._. Third_NNP ,_, we_PRP
        have_VBP not_RB demonstrated_VBN fully_RB that_IN the_DT stimulus–secretion_NN coupling_NN apparatus_NN in_IN IPCs_NNP is_VBZ
        similar_JJ to_TO that_DT in_IN pancreatic_JJ islets_NNS ._. While_IN insulin_NN release_NN by_IN IPCs_NNP produced_VBD here_RB appears_VBZ
        to_TO be_VB glucose-sensitive_JJ ,_, both_DT in_IN vitro_NN and_CC in_IN vivo_NN ,_, future_JJ work_NN should_MD elaborate_VB whether_IN
        IPC_NNP insulin_NN is_VBZ stored_VBN in_IN dense-core_JJ secretory_NN vesicles_NNS ,_, and_CC whether_IN secretogogues_NNS or_CC
        secretion_NN potentiators_NNS other_JJ than_IN glucose_NN (_( like_IN amino_JJ acids_NNS or_CC sulfonylureas_NNS )_) stimulate_VB
        insulin_NN release_NN by_IN IPCs_NNP ,_, like_IN in_IN pancreatic_JJ islets_NNS ._. Lastly_NNP ,_, we_PRP have_VBP not_RB ameliorated_JJ glucose_NN
        regulation_NN in_IN diabetic_JJ animal_NN models_NNS with_IN the_DT human_JJ IPCs_NNP described_VBD here_RB ._. Serum_NNP levels_NNS of_IN
        insulin_NN C-_NNP peptide_NN expression_NN achieved_VBD following_VBG IPC_NNP transplantation_NN in_IN glucose-challenged_JJ
        mice_NNS were_VBD less_JJR than_IN 1_CD %_NN of_IN normal_JJ (_( see_VB Figure_NN 4_LS )_) ._. Thus_RB ,_, we_PRP did_VBD not_RB attempt_VB IPC_NNP
        transplantations_NNS in_IN overtly_RB diabetic_JJ animals_NNS ,_, since_IN prior_JJ studies_VBZ suggest_VBP that_DT insulin_NN
        production_NN at_IN 10_CD %_NN of_IN normal_JJ (_( or_CC greater_JJR )_) may_MD be_VB required_VBN to_TO improve_VB glucose_NN regulation_NN in_IN
        diabetic_JJ patients_NNS and_CC animal_NN models_NNS [_NN 10_CD ,_, 41_CD ]_NN ._. Additional_JJ studies_NNS to_TO test_VB the_DT impact_NN of_IN
        transplanted_VBN IPCs_NNP in_IN animal_NN models_NNS of_IN diabetes_NN therefore_RB await_VBP production_NN of_IN IPCs_NNP capable_JJ
        of_IN insulin_NN secretion_NN at_IN levels_NNS higher_JJR than_IN achieved_VBN here_RB ._.
        Nevertheless_RB ,_, compared_VBN to_TO other_JJ methods_NNS for_IN IPC_NNP development_NN from_IN human_JJ stem_NN cells_NNS
        [_NN 13_CD ,_, 44_CD ]_NN ,_, our_PRP$ methods_NNS produced_VBD insulin_NN at_IN the_DT highest_JJS levels_NNS yet_RB achieved_VBN from_IN an_DT
        expandable_JJ ,_, human_JJ stem-cell-derived_JJ tissue_NN ._. Multiple_NNP experimental_JJ approaches_NNS were_VBD taken_VBN to_TO
        demonstrate_VB that_IN these_DT IPCs_NNP transcribe_VBP ,_, translate_VB ,_, and_CC secrete_NN insulin_NN ,_, and_CC to_TO rule_VB out_RP the_DT
        possibility_NN that_DT insulin_NN measured_VBN in_IN IPCs_NNP derived_VBD from_IN the_DT culture_NN media_NNS ._. In_IN vitro_NN studies_NNS
        demonstrate_VBP that_IN IPCs_NNP release_NN insulin_NN in_IN a_DT glucose-responsive_JJ manner_NN ,_, like_IN islets_NNS ._.
        Moreover_RB ,_, IPCs_NNP transplanted_VBN into_IN mice_NNS remained_VBD differentiated_JJ and_CC released_VBN circulating_VBG
        human_JJ insulin_NN in_IN a_DT glucose-dependent_JJ manner_NN ._. Thus_RB ,_, for_IN the_DT first_JJ time_NN ,_, we_PRP demonstrate_VBP
        moderately_RB efficient_JJ production_NN of_IN glucose-responsive_JJ IPCs_NNP from_IN an_DT expandable_JJ population_NN of_IN
        human_JJ stem_NN cells_NNS ._. Current_JJ islet_NN transplantation_NN methods_NNS require_VBP an_DT estimated_VBN 5_CD ×_NN 10_CD
        8_CD to_TO 10_CD
        9_CD β-cells_JJ per_IN recipient_JJ [_NN 45_CD ]_NN ._. From_IN 10_CD
        6_CD cells_NNS at_IN stage_NN 2_CD ,_, we_PRP produced_VBD an_DT average_NN of_IN 200_CD –_NN 400_CD clusters_NNS with_IN
        approximately_RB 2_CD ,_, 000_CD cells_NNS per_IN cluster_NN ;_: approximately_RB 25_CD %_NN of_IN these_DT cells_NNS are_VBP C-_NNP peptide_NN
        +_NN and_CC release_NN 0_CD ._. 5_CD %_NN –_NN 1_CD %_NN of_IN C-_NNP peptide_NN secreted_JJ by_IN β-cells_JJ ._. Based_VBN strictly_RB
        on_IN these_DT yields_NNS ,_, we_PRP would_MD need_VB to_TO expand_VB IPC_NNP production_NN approximately_RB 10_CD
        5_CD -_: fold_VB to_TO meet_VB the_DT need_NN for_IN one_CD transplantation_NN ._. Undifferentiated_NNP NSs_NNP
        can_MD be_VB readily_RB expanded_VBN through_IN at_IN least_JJS a_DT dozen_NN passages_NNS [_NN 14_CD ]_NN ,_, suggesting_VBG sufficient_JJ cell_NN
        numbers_NNS could_MD be_VB generated_VBN to_TO “ scale_VB up_RP” this_DT protocol_NN for_IN transplant-based_JJ therapies_NNS ._.
        We_PRP did_VBD not_RB exhaust_VB all_DT possible_JJ factor_NN combinations_NNS in_IN our_PRP$ study_NN :_: we_PRP speculate_VBP that_IN
        further_JJ method_NN refinements_NNS may_MD improve_VB the_DT efficiency_NN of_IN NS_NNP conversion_NN into_IN IPCs_NNP ,_, as_RB well_RB
        as_IN IPC_NNP insulin_NN synthesis_NN and_CC stimulus–secretion_NN coupling_NN ,_, the_DT hallmark_NN functions_NNS of_IN mature_VBP
        β-cells_JJ ._. If_IN so_RB ,_, then_RB human_JJ neural_NN stem_NN cells_NNS may_MD serve_VB as_IN a_DT valuable_JJ model_NN for_IN elucidating_VBG
        the_DT mechanisms_NNS and_CC factors_NNS that_WDT regulate_VB neuroendocrine_NN cell_NN differentiation_NN ._. For_IN instance_NN ,_,
        addition_NN of_IN glucagon-like_JJ peptide-_NN 1_CD ,_, TGF-β_NNP ligands_NNS ,_, or_CC other_JJ factors_NNS that_WDT potentiate_NN β-cell_JJ
        maturation_NN ,_, growth_NN ,_, and_CC insulin_NN secretion_NN [_NN 46_CD ,_, 47_CD ,_, 48_CD ]_NN may_MD improve_VB the_DT methods_NNS described_VBD
        here_RB ._. Because_IN our_PRP$ method_NN is_VBZ based_VBN solely_RB on_IN extracellular_NN factor_NN modulation_NN ,_, in_IN the_DT absence_NN
        of_IN genetic_JJ manipulations_NNS ,_, it_PRP could_MD serve_VB as_IN the_DT basis_NN for_IN developing_VBG replacement_NN islets_NNS
        from_IN a_DT wide_JJ range_NN of_IN human_JJ stem_NN cells_NNS ,_, including_VBG neural_NN stem_NN cells_NNS and_CC ES_NNP cells_NNS ._.
      
      
        Supporting_VBG Information_NNP
        
          Accession_NNP Numbers_NNPS
          The_DT National_NNP Center_NNP for_IN Biotechnology_NNP Information_NNP (_( www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN )_) accession_NN
          numbers_NNS for_IN the_DT genes_NNS and_CC gene_NN products_NNS discussed_VBN in_IN this_DT paper_NN are_VBP 
          brachyury_NN (_( AF_NNP 012130_CD )_) ,_, 
          Cdx_NNP 1_CD (_( NM_NNP __NN 000209_CD )_) ,_, 
          Desert_NNP hedgehog_NN (_( NM_NNP __NN 021044_CD )_) ,_, 
          En_NNP 1_CD (_( NM_NNP __NN 001426_CD )_) ,_, 
          flk-_NN 1_CD (_( AF_NNP 035121_CD )_) ,_, 
          FoxA_NNP 3_CD (_( NM_NNP __NN 004497_CD )_) ,_, GAPDH_NNP (_( NM_NNP __NN 002046_CD )_) ,_, GFAP_NNP (_( NM_NNP __NN 002055_CD )_) ,_, glucokinase_NN
          (_( M_NNP 90299_CD )_) ,_, 
          Hb_NNP 9_CD (_( NM_NNP __NN 005515_CD )_) ,_, 
          Hoxb_NNP 9_CD (_( NM_NNP __NN 024017_CD )_) ,_, 
          Hoxc_NNP 6_CD (_( NM_NNP __NN 004503_CD )_) ,_, human_JJ insulin_NN cDNA_NN (_( J_NNP 00265_CD )_) ,_, 
          Indian_JJ hedgehog_NN (_( NM_NNP __NN 002181_CD )_) ,_, 
          Isl_NNP 1_CD (_( NM_NNP __NN 002202_CD )_) ,_, MAP_NNP 2_CD (_( U_NNP 01828_CD )_) ,_, myelin_NN basic_JJ protein_NN (_( M_NNP 13577_CD )_) ,_, 
          myosin_NN light_JJ chain-_NN 2_CD (_( X_NNP 57542_CD )_) ,_, Nestin_NNP (_( NM_NNP __NN 006617_CD )_) ,_, 
          ngn_NN 3_CD (_( AF_NNP 234829_CD )_) ,_, 
          Nkx_NNP 6_CD ._. 1_LS (_( NM_NNP __NN 006168_CD )_) ,_, 
          NRSF_NNP /_NN REST_NNP (_( U_NNP 13879_CD )_) ,_, Olig_NNP 2_CD (_( NM_NNP __NN 005806_CD )_) ,_, 
          Pdx_NNP 1_CD (_( NM_NNP __NN 000209_CD )_) ,_, 
          Ptc_NNP (_( U_NNP 59464_CD )_) ,_, RAR-α_NNP (_( NM_NNP __NN 000964_CD )_) ,_, RAR-β_NNP (_( BC_NNP 060794_CD )_) ,_, RAR-γ_NNP (_( NM_NNP __NN 000966_CD )_) ,_, 
          Shh_NNP (_( L_NNP 38518_CD )_) ,_, 
          Smo_NNP (_( AH_NNP 007453_CD )_) ,_, 
          β-globin_JJ (_( NM_NNP __NN 000518_CD )_) ,_, and_CC β-tubulin_JJ III_NNP (_( BC_NNP 000748_CD )_) ._.
        
      
    
  
